Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Bastox Sep. 21 at 10:32 PM

$ABCL Breaking News! Moonsludge has changed his name to: Always Wrong. It fits perfectly

0 · Reply

8008track Sep. 21 at 8:33 PM

$ABCL green is green

0 · Reply

Bastox Sep. 21 at 8:10 PM

$ABCL Oh no, Moonlet. How is that you can be so wrong so often??

1 · Reply

Bastox Sep. 21 at 7:57 PM

$ABCL Moon Moron. Wait….wait. You said $13.30’s by the close and you say you’re always right. Can you help us understand?

0 · Reply

Bastox Sep. 21 at 7:39 PM

$ABCL Moonage, wrong again? Are you embarrassed?

0 · Reply

Bastox Sep. 21 at 7:31 PM

$ABCL Moonie! You said $13.30’s by close and you say you’re always right What happened? Could you be wrong? Oh no! Again with the wrong?

0 · Reply

Stocktradesmoon Sep. 21 at 7:16 PM

$ABCL 🚨READ this 👇🏻👇🏻 👀 ‼️

2 · Reply

Bastox Sep. 21 at 7:15 PM

$ABCL StockieMoon ”I have been right all along”. Haha You’re wrong almost every day and will be wrong today.

0 · Reply

Stocktradesmoon Sep. 21 at 6:56 PM

$ABCL I told you ALL WE Would go GREEN!! Now this is your CHANCE to GET IN We are heading Mid $13.55’sss VERY FAST!!💨 I have been Right ALL ALONG…Listen!! We are going to be MUCH HIGHER today by END of DAY and Especially by END of WEEK!! The CHART 📈 is BREAKING-OUT it wants IPO prices $20-$23’ss! We got A lot of GREAT NEWS Out and the Conference Call from Our CEO CARL was a HOMERUN!! It’s a MUST LISTEN!! 🎧 That’s NOT ALL! And Now we got some Announcements of more things to Come! With the Largest IMS MENOPAUSE Convention Conference HAPPENING in a few days we are going NEW 52 WEEK HIGHS‼️ 🚨RUMOR is $ABCL wants $ABVX in a cash and equity deal!!!! That’s a HUGE DEAL…that would send us $25-30’sss OVERNIGHT‼️ What are you waiting for??…to Pay Higher Prices..$ABCL is a gift at these prices all institutions who have bought paid about $25-30 per share!! 🫣 🚨Our Phase II Results were so Impressive‼️ Now 12 Week Data 📊 going to be released in a few days @ Largest IMS Menopause Conference!!

2 · Reply

Stocktradesmoon Sep. 21 at 6:03 PM

$ABCL 🚨Can’t imagine you plan a Menopause Therapeutic Data Release at the Largest 2026 IMS World Menopause Conference to Share bad results?! ABSOLUTELY 💯 NOT! LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.55’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️ 🚨IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss! Good luck keeping this down!! We are in a BREAK-OUT $17-$23’ss by next WEEK! SMART Money Positioning ahead of the Pipeline. Best 30 minute Conference Call I HAVE EVER LISTENED TOO!!! 🚨 🚨🚨CEO CARL Quoted Phase II RESULTS were so IMPRESSIVE that “Patients were “CURED” after 4 weeks. From 10events a day to “ZERO” 🤯 BLACKROCK INC. THE #1 Financial Institution went 15M to 45M $ABCL Shares‼️

2 · Reply

AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause

Sep 16, 2026, 4:05 PM EDT - 5 days ago

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Sep 9, 2026, 2:10 PM EDT - 12 days ago

AbCellera Biologics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 2, 2026, 4:05 PM EDT - 19 days ago

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

2026-08-25T16:06:05.000Z - 27 days ago

AbCellera rises 17.0%

2026-08-25T14:06:36.000Z - 27 days ago

AbCellera rises 10.7%

Aug 13, 2026, 12:05 AM EDT - 5 weeks ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-08-11T20:05:47.000Z - 5 weeks ago

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 5 weeks ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 5 weeks ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 6 weeks ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 6 weeks ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 6 weeks ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 6 weeks ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 6 weeks ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 6 weeks ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 6 weeks ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 6 weeks ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 6 weeks ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 6 weeks ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 6 weeks ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 7 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 7 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 2 months ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 3 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 3 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 4 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 5 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 6 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 7 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 8 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 8 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 8 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 9 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Bastox Sep. 21 at 10:32 PM

$ABCL Breaking News! Moonsludge has changed his name to: Always Wrong. It fits perfectly

0 · Reply

8008track Sep. 21 at 8:33 PM

$ABCL green is green

0 · Reply

Bastox Sep. 21 at 8:10 PM

$ABCL Oh no, Moonlet. How is that you can be so wrong so often??

1 · Reply

Bastox Sep. 21 at 7:57 PM

$ABCL Moon Moron. Wait….wait. You said $13.30’s by the close and you say you’re always right. Can you help us understand?

0 · Reply

Bastox Sep. 21 at 7:39 PM

$ABCL Moonage, wrong again? Are you embarrassed?

0 · Reply

Bastox Sep. 21 at 7:31 PM

$ABCL Moonie! You said $13.30’s by close and you say you’re always right What happened? Could you be wrong? Oh no! Again with the wrong?

0 · Reply

Stocktradesmoon Sep. 21 at 7:16 PM

$ABCL 🚨READ this 👇🏻👇🏻 👀 ‼️

2 · Reply

Bastox Sep. 21 at 7:15 PM

$ABCL StockieMoon ”I have been right all along”. Haha You’re wrong almost every day and will be wrong today.

0 · Reply

Stocktradesmoon Sep. 21 at 6:56 PM

2 · Reply

Stocktradesmoon Sep. 21 at 6:03 PM

2 · Reply

Stocktradesmoon Sep. 21 at 5:19 PM

$ABCL LAST CHANCE!! This is the time to LOAD UP!!! Buy all you can here at $12.55’s. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️And with all the great NEWS OUT and then we have the IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨AT the Conference they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss!!! Good luck keeping this down!!! We are in a BREAK-OUT $17-$23’sss by next WEEK!!! 🚨$ABCL can’t imagine you plan a menopause therapeutic data release at the 2026 IMS World Menopause conference to share bad results! Q2 13Fs: BlackRock opened a ~3.8M-share position (~$30M), with Man Group and HSBC also starting positions. Inst own 61%Cantor Healthcare Conference on Sep 9 kept it in front of healthcare investors. Smart money positioning ahead of the pipeline. $ABCL 📈 looks better EVERYDAY‼️

1 · Reply

Stocktradesmoon Sep. 21 at 5:15 PM

$ABCL HERE WE GO!! $13’sss LAST Chance! Get in NOW or Regret by this afternoon when we are at $13.30’sss

0 · Reply

DeMampCamp Sep. 21 at 5:04 PM

$ABCL Loving the consolidation happening, right near our almost 4 year highs! I'm totally fine in this area until our next catalyst!

0 · Reply

Stocktradesmoon Sep. 21 at 4:21 PM

1 · Reply

villaspecialisten Sep. 21 at 4:08 PM

$ABCL An honest and objective assessment of $ABCL is this: The potential is huge. If the Phase 2 results prove durable over time and can be replicated in larger trials, ABCL635 could move into Phase 3 with a very compelling clinical profile. If Phase 3 then confirms those results, the upside could be substantial. But everyone needs to stay sober about the risk. This is still biotech. There are several major hurdles left, and if the results fail to hold up in larger or longer trials, the downside could be dramatic. Im still bullish and invested in this with a 7% portfolio stake.

1 · Reply

Stocktradesmoon Sep. 21 at 3:32 PM

$ABCL This is the time to LOAD UP!!! Buy all you can here at $12.55’sss. We about to Squeeze to Mid-13’sss. It’s going to HAPPEN so FAST!!! MM’s and Shorts can NO LONGER keep $ABCL back at Lower Prices!! The Chart 📈 is PRIMED to SQUEEZE‼️And with all the great NEWS OUT and then we have the IMS LARGEST MENOPAUSE Convention Conference in a few days!!! 😮 🤯 🚨Then they are going to be Releasing the PHASE II RESULTS 12 WEEK DATA 📊 ( the 90 Days) yea we going to the $20’sss!!! Good luck keeping this down!!! We are in a BREAK-OUT $17-$23’sss by next WEEK!!! 🚨$ABCL can’t imagine you plan a menopause therapeutic data release at the 2026 IMS World Menopause conference to share bad results! Q2 13Fs: BlackRock opened a ~3.8M-share position (~$30M), with Man Group and HSBC also starting positions. Institutions own 61%+ of the stock. Cantor Healthcare Conference on Sep 9 kept it in front of healthcare investors. Smart money positioning ahead of the pipeline. $ABCL 📈 looks better EVERYDAY‼️

0 · Reply

Stocktradesmoon Sep. 21 at 3:12 PM

1 · Reply

Stocktradesmoon Sep. 21 at 2:42 PM

$ABCL READ IT!!! 🚨 😮 🤯 ****Disclosure of Phase II RESULTS the 12-Week Data (the 90 DAYS) @the Largest IMS MENOPAUSE Conference Convention in the WORLD 🌎 ***** $ABCL NEWS is OUT!! PART 2/2 🚨Key points to watch for in particular 👇 ⏳ Durability of efficacy after 4 weeks 📊 Patient-specific responses and detailed data on complete resolution (complete symptom resolution) 🛡️ More detailed safety data 💉 Additional information supporting dosing and administration intervals for Phase 3 🚨Disclosure of Phase II RESULTS of 12-week data (90 Days)😮 🤯 ‼️ That said, the significance is clear. 🧬 AbCellera is still officially describing 635 as;potential best-in-class and is now taking its first GPCR clinical asset to the stage of full validation on the academic platform. 🚀 This isn’t an announcement of a new clinical success. But October 1 marks the next checkpoint to see how much deeper data will back up the Phase 2 success of 635. #ABCL #AbCellera #ABCL635

2 · Reply

FGA Sep. 21 at 2:29 PM

$ABCL These idiots keep playing with themselves on the daily and I'm pretty sure it continues at their home!🤣😭😂 Patience is the key to GRAND money!

1 · Reply

Stocktradesmoon Sep. 21 at 2:24 PM

$ABCL We are on a BREAK-OUT MODE!! More people have Read and Digested all the Great NEWS 🗞️ that has come out and the Call With our CEO CARL!! On top of all that we got NEWS about being Presented at the LARGEST IMS WORLD CONGRESS ON MENOPAUSE 2026 Convention Conference in the WORLD 🌎 🗺️!!! It’s NEXT WEEK!!!! $ABCL 🚨 can’t imagine you plan a menopause therapeutic data release at the 2026 IMS World Menopause conference to share bad results! 🚨 We are in the RIGHT TIME…RIGHT PLACE!!! $ABCL Beautiful Chart 📈, Huge buys on LEVEL II, GREAT CONSOLIDATION ✅ 🚨We are going to be somewhere between $17’ss-$23’sss by Conference next week. Listen and watch!!! Trust me and GET in!!! Don’t MISS OUT!!!

0 · Reply

Stocktradesmoon Sep. 21 at 2:09 PM

$ABCL YES!! 👏

0 · Reply

Stocktradesmoon Sep. 21 at 2:08 PM

$ABCL 400,000 buy on LEVEL II!!!! Something has a leaked some Partnership or deal?!!!!

0 · Reply

Market Cap	3.87B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,425,800
Avg Vol	6,957,600
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	81%
Beta	1.32
Analysts	Strong Sell
Price Target	$17.12